Israel kills at least 66 Palestinians in Gaza: medicsNoneColombia shares lower at close of trade; COLCAP down 0.51%
The trade group of Colorado hospitals is preparing for a political battle at the state Capitol to maintain a federal drug discount program that the group says benefits nearly 70 hospitals statewide. Critics of the program known as 340B argue it has been widely abused and misused, particularly by large hospitals. While it is a federal program, Julie Lonborg, senior vice president of Colorado Hospital Association, said her group will turn to the Colorado state legislature next year to push legislation to protect hospitals from losing funding. The program, she said, is under attack by the pharmaceutical industry. The group and officials from several hospitals hosted a virtual roundtable on Dec. 10 to discuss maintaining funding they argued is needed to keep hospitals on track. In the meeting organized by the trade group, Lonborg said 68 of the state’s 88 hospitals qualify for the 340B program. The federal 340B Drug Pricing Program, established in 1992 as part of the Public Health Service Act, allows eligible healthcare organizations to purchase outpatient drugs at a discount from manufacturers. In an email to Colorado Politics, Cara Welch, the group's communications director, said protecting 340B is a priority. No legislation has been drafted yet and no sponsors at the Capitol have been found, Welch said. Welch said that, since 2020, pharmacies have started limiting hospitals' participation in the program, adding that states have oversight, though 340B is a federal program. Last month, a three-member panel attended a healthcare forum in Denver said large hospitals are abusing the program that is supposed to help pay healthcare costs for low-income families. The panel said fixing the program cannot happen at the state level, maintaining Congress must fix it. During the Nov. 12 forum, William Smith, a senior fellow at the Pioneer Institute, said pharmacy benefit managers (PBMs) and large hospitals have learned how to profit from the program. For example, a cancer drug costing around $200,000 is only $25,000 for hospitals with 340B status. However, the hospital is still billing insurance companies for $200,000 and “pocketing $175,000 in profits," he said. “That's really what's driving this program — is the ability of hospitals to arbitrage the discounts,” Smith said. “And what's happened is hospitals have gone out into wealthy neighborhoods and have purchased physician practices, particularly physician practices that prescribe high-cost drugs, like rheumatologists or oncologists, and they bought them up so that they could charge more to the discounts for profit.” Critics also said the program has become mismanaged and underregulated due to staff shortages at the Health Resources and Services Administration, which oversees it. Others said hospitals have not been transparent about using 340B funding. Courtney Christian, deputy vice chair of policy and research for PhRMA, said the solution is not be to eliminate the 340B program because it has value to hospitals when applied correctly, noting that its primary purpose is to help patients in need and support charitable programs. The hospital association said keeping the program is vital. The main question is whether state lawmakers would make changes or leave the issue completely up to the federal government. “The powerful pharmaceutical industry has mounted a coordinated national effort to weaken 340B, even though this discount program accounts for 3% of the drug companies’ profits globally," the association said. "Despite the minimal impact to pharmaceutical companies, 340B is an essential lifeline for 68 participating Colorado hospitals with; 89% of which operate with low or negative margins.” Meanwhile, Kevin Forbush, the 340B program director at Intermountain Health in Brighton, said he disagrees with the assertion that the program does not have oversight, noting he has taken part in audits for the last 10 years. “This is a highly regulated program that’s administered by the federal government, Forbush said. “I, myself have been through six of these audits. They are very intense.” Forbush described a system where hospitals must undergo a process to meet stringent criteria. Under the 340B program, a patient who needs blood thinner medication pays 28 cents when the regular cost is $500; hence, the 340B program, which aims to bring down drug costs, works, he said. Chris Thomas, the president and CEO of Community Hospital in Grand Junction, said hospitals are already operating on thin margins, and “340B funding for us is absolutely critical.” For some hospitals barely operating in the black, hospital officials say losing funding could force them to operate at a deficit. UCHealth Vice President Dan Weaver said that UCHealth is the state’s largest MedCaid provider and that it continues to see the number of uninsured patients grow. “340B is extremely important to us,” he said. “Not only do some of the of our hospitals qualify for 340B because of the amount of uncompensated care that they provide, but 340B makes that uncompensated care possible.” Being in an urban community, Thomas said the Community Hospital is five miles from another hospital and considered too big to be a critical access facility. With 340B funding, Thomas said, the hospital has invested in a better OB and midwife program. “We embed our midwives,” he said. “They go into our safety net clinic on a weekly basis and see patients on a sliding scale. We know that giving prenatal care early and often saves money, saves lives and improves the health of our community.” At the November forum, Jonathan Campbell, the chief science officer for the National Pharmaceutical Council, said those who are abusing the 340B program are costing the healthcare industry an estimated $5 billion.ATLANTA — Georgia’s Republican attorney general, Chris Carr, said Thursday that he’s running for governor in 2026, becoming the first major candidate from either party to announce a bid. Prominent Republicans and Democrats are eyeing the seat, which will be open in two years after term-limited Republican Gov. Brian Kemp leaves the office. Other potential Republican contenders include Lt. Gov. Burt Jones and Secretary of State Brad Raffensperger, while the Democratic field is less well-defined. Carr is portraying himself as the best candidate to continue steady Republican leadership in the mold of the late U.S. Sen. Johnny Isakson, former Gov. Nathan Deal and Kemp. “I’ve seen what it takes to be successful,” Carr told The Associated Press in a phone interview. “And I want to run as the proven conservative who will create jobs for hardworking Georgians, keep our families and neighborhoods safe and vigorously defend our Constitution and freedoms.” Carr has aligned closely with Kemp but could face opposition from President-elect Donald Trump and his supporters in a primary election. Jones has been close to Trump and would likely angle for his endorsement. By contrast, Trump endorsed primary opponents who ultimately lost to both Carr and Raffensperger in 2022, fueled by his displeasure that neither Carr nor Raffensperger backed Trump’s attempts to overturn his 2020 presidential election loss in Georgia. Carr said he was confident that he could win on issues and appeal to enough voters to win a Republican primary, despite his past differences with Trump. “This race isn’t going to be about how loud somebody yells or screams, it’s going to be about a conservative record,” he said. “And I’m the one that has that.” It’s exceptionally early to announce a 2026 political bid. Customarily, statewide candidates in Georgia would announce sometime after 2025’s legislative session. But Carr let it be known more than a year ago that he was lining up donors for a run. That’s in part because Jones and Raffensperger are much more wealthy than Carr. Carr filed papers with the Georgia Ethics Commission Thursday creating a campaign committee to raise money for the governor’s race. Announcing now could help Carr lock down donors, especially because he won’t be able to raise money for his state campaign account during the three-month legislative session that convenes on Jan. 13. The attorney general’s office in Georgia traditionally has been preoccupied with defending civil lawsuits brought against the state and could only aid in a prosecution if a local district attorney requested help. But Republican lawmakers have given Carr increasing powers to directly prosecute criminals. In 2019, lawmakers gave Carr the authority to create a human trafficking prosecution unit. Carr’s office says the unit has convicted 50 people, participated in 325 investigations and assisted more than 200 victims. In 2022, lawmakers directed Carr to create a statewide gang prosecution unit that now has offices in Atlanta, Albany, Augusta, Columbus, Macon and southeast Georgia. That unit has secured more than 40 convictions and indictments against more than 140 people. “Nobody’s going to come here and locate a business or a job if they don’t feel safe,” Carr said, calling his office’s expansion of prosecutions “very successful.” Gov. Nathan Deal picked Carr to become Commissioner of Economic Development in 2013 after another old Isakson hand, Chris Cummiskey, left to work for the Southern Co., the Atlanta-based utility giant. Deal put a major emphasis on economic development as Georgia tried to dig out from the wreckage of the Great Recession, and Carr helped facilitate projects worth more than $14 billion in investment that helped create more than 83,000 jobs. Deal promoted Carr to attorney general in 2016 after Sam Olens resigned to become president of Kennesaw State University. Carr hadn’t earned a living practicing law for years and had never personally tried a case. But he wasn’t challenged in the Republican primary in 2018 and narrowly beat Democrat Charlie Bailey in the general election. Georgia’s attorney general doesn’t face term limits, meaning Carr could have chosen to run for reelection in 2026.
California Voice: ‘It’s 5 o’clock somewhere’ is no joke if you’ve seen alcohol’s toll
( MENAFN - EIN Presswire) Clinical Communication And Collaboration Global market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033 The Business Research Company's Early Year-End Sale! Get up to 30% off detailed market research reports-for a limited time only! LONDON, GREATER LONDON, UNITED KINGDOM, December 13, 2024 /EINPresswire / -- The Business Research Company's Early Year-End Sale! Get up to 30% off detailed market research reports-limited time only! Is Rise in Telemedicine and Remote Care Services Driving the Growth of the Clinical Communication And Collaboration Market? The clinical communication and collaboration market size has seen swift expansion in recent years. It is projected to grow from $2.56 billion in 2023 to $3.04 billion in 2024, exhibiting a compound annual growth rate CAGR of 19.0%. This substantial growth in the historic period has been driven by several factors such as the increase in adoption of digital health solutions, significant growth in telemedicine and remote care services, increased focus on patient-centered care, a rise in the use of electronic health records EHRs, and substantial growth in mobile health mHealth applications. Preview the detailed advancements in Clinical Communication and Collaboration Market: What's the Future for the Clinical Communication and Collaboration Market? The clinical communication and collaboration market is anticipated to see further growth in the years to come. It is predicted to expand to $6.15 billion in 2028 at a compound annual growth rate CAGR of 19.3%. The growth in the forecast period can be attributed to the increasing adoption of mobile health technologies, soaring demand for real-time patient data access, rising trend of value-based care models, growing emphasis on data security and privacy, and an increase in the number of connected healthcare devices. Futuristic trends in the forecast period encompass the adoption of artificial intelligence AI powered tools, the implementation of secure messaging platforms, the development of interoperable systems, advancements in telemedicine, and the integration of wearable health devices. Grab your copy of the comprehensive report: How Is Home Healthcare Driving Growth In The Clinical Communication And Collaboration Market? The impressive shift towards home healthcare is expected to fuel the growth of the clinical communication and collaboration market in the future. Home healthcare includes a range of medical services provided in a patient's home, including chronic disease management, rehabilitation, infusion therapy, and personalized care plans. This enables patients to obtain treatment in a comfortable and cost-effective setting. How Are Major Players Influencing The Clinical Communication and Collaboration Market? Major players in the clinical communication and collaboration market include Microsoft Corporation, Intel Corporation, Cisco Systems Inc., Oracle Corporation, NEC Corporation, Siemens Healthineers AG, Koninklijke Philips N.V., Stryker Corporation, Zebra Technologies Corporation, Omnicare Inc., and many others. What Innovations Are Emerging In The Clinical Communication And Collaboration Market? In an effort to maintain a competitive edge in the industry, key players in the clinical communication and collaboration market are focused on developing innovative solutions. How Is The Clinical Communication And Collaboration Market Segmented? The clinical communication and collaboration market can be divided based on the following categories - 1 By Component: Solution, Services 2 By Deployment: Hosted, On-Premise 3 By End User: Hospitals, Clinical Labs, Physicians, Other End Users What Are The Regional Insights Into The Clinical Communication And Collaboration Market? North America dominated as the largest region in the clinical communication and collaboration market in recent times. However, Asia-Pacific is expected to emerge as the fastest-growing region in the forecast period. Browse more similar reports- Clinical Chemistry Global Market Report 2024 Pediatric Clinical Trials Global Market Report 2024 AI In Clinical Trials Global Market Report 2024 About The Business Research Company Learn More About The Business Research Company. With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game. Contact us at: The Business Research Company: Americas +1 3156230293 Asia +44 2071930708 Europe +44 2071930708 Email us at ... Follow us on: LinkedIn: YouTube: Global Market Model: global-market-model Oliver Guirdham The Business Research Company +44 20 7193 0708 email us here Visit us on social media: Facebook X LinkedIn Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above. MENAFN12122024003118003196ID1108988703 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.WASHINGTON (AP) — President Joe Biden's decision to break his word and pardon his son Hunter has spurred a broader discussion about what else he should be doing with the broad clemency powers of the presidency before he leaves office in January, including whether he should be pardoning Donald Trump. Biden on Tuesday ducked questions about his son, ignoring calls for him to explain his reversal as he was making his first presidential trip to Angola . He dismissed shouted questions about the matter with a laugh during a meeting with Angolan President João Lourenço at the presidential palace, telling the Angolan delegation: “Welcome to America.” Biden was not scheduled to take questions from the press during his trip to Africa, and he has largely avoided interactions with reporters since President-elect Trump’s victory last month. Biden’s decision to offer his son a blanket pardon for actions over the past 11 years has sparked a political uproar in Washington, after the president repeatedly had said he would not use his extraordinary powers for the benefit of his family. Biden claimed that the Justice Department had presided over a “miscarriage of justice” in prosecuting his son, using some of the same language that Trump uses to describe his own legal predicaments. Biden's reversal drew criticism from many Democrats , who are working to calibrate their approach to Trump as he prepares to take over the Oval Office in seven weeks. There is concern the pardon — and Biden's claims that his son was prosecuted for political reasons — will erode their ability to push back on the incoming president’s legal moves. And it has threatened to cloud Biden's legacy as he prepares to leave office on Jan. 20. Hunter Biden is the closest presidential relative ever to be granted clemency, but other leaders have pardoned family members and close friends. Bill Clinton pardoned his brother Roger for drug charges after Roger Clinton had served his sentence. By the time Trump left office after his first term, he had issued 144 pardons, which included Charles Kushner , the father of his son-in law, Jared Kushner. He also pardoned fervent supporters Steve Bannon, Roger Stone, Paul Manafort, Michael Flynn and other people convicted in special counsel Robert Mueller’s Russia investigation. In the months after the 2020 election, Trump and his allies were trying to overturn his loss, a failed effort that culminated in the violent riot by his supporters at the Capitol on Jan. 6, 2021. There were discussions at the time over whether Trump would preemptively pardon some of those involved in the effort — and maybe even himself — before he left office. But that never happened. Now, Democrats are having similar discussions about preemptive pardons on their side because of Trump's rhetoric on the campaign trail. He's made no secret of his desire to seek revenge on those who prosecuted him or crossed him. He talks about "enemies from within." He's circulated social media posts that call for the jailing of Biden, Vice President Kamala Harris, former Vice President Mike Pence and Sens. Mitch McConnell and Chuck Schumer. He's also taken aim at Liz Cheney, a conservative Republican who campaigned for Harris, promoting a social media post that suggested he wanted military tribunals to punish her because she was guilty of treason. Sen. Ed Markey, a Massachusetts Democrat, said last week on Boston Public Radio that Biden might consider broad pardons to protect people against whatever wrath Trump may seek, but also as a way to move the country past this acrimonious and divided time. “I think that without question, Trump is going to try to act in a dictatorial way, in a fascistic way, in a revengeful first year at least of his administration toward individuals who he believes harmed him,” Markey said. Presidents enjoy expansive pardon powers when it comes to federal crimes . That includes granting clemency to people who have not yet been charged, as President Gerald Ford did in 1974 when he pardoned his predecessor, Richard Nixon, over the Watergate scandal. The decision at the time caused an uproar but has been seen in the ensuing decades as a move that helped restore order. Markey cited Ford's pardon as a way for the country “just to close that chapter and move on to a new era.” Biden could do the same, Markey said, to help the country move on “to an agenda that deals with the ordinary families.” Sen. Joe Manchin, the Democrat-turned-independent from West Virginia, took it a step further and suggested Biden should even pardon Trump for his efforts to overturn the 2020 election, federal charges that are now evaporating with Trump's upcoming return to the White House. “Why don't you go ahead and pardon Donald Trump for all his charges?" he said in an interview with CNN. “It would have gone down a lot more balanced. I'm just saying, wipe them out.” At the same time, Democratic lawmakers and criminal justice reformers are pushing Biden to grant pardons to broad groups of Americans. Democrats Ayanna Pressley, Jim Clyburn and Mary Gay Scanlon wrote to Biden on Nov. 20, asking him to use his clemency powers to "address longstanding injustices in our legal system, and set our nation on the path toward ending mass incarceration.” The letter, also signed by 61 others, suggested Biden could use his powers to send a powerful message of criminal justice reform and "rectify unjust and unnecessary criminal laws passed by Congress and draconian sentences given by judges.” “We encourage you to use your clemency powers to help broad classes of people and cases, including the elderly and chronically ill, those on death row, people with unjustified sentencing disparities, and women who were punished for defending themselves against their abusers,” they wrote. So far, Biden has pardoned 25 people. Most presidents tend to grant a flurry of clemency requests at the end of their terms, and it's likely Biden will do the same. White House press secretary Karine Jean-Pierre has said Biden is “thinking through that process very thoroughly.” Weissert reported from Luanda, Angola.
A RISE in shareholder activism in Japan is poised to fuel a new wave of management buyouts by founding families, after the battle for 7-Eleven’s parent company prompted a US$58 billion takeover offer from the Ito dynasty that built the retail giant. Seven & i Holdings vice-president Junro Ito swooped in last month with an offer to take private the company founded by his late father in what would be the largest ever management buyout (MBO). Ito’s “white knight” bid appears designed to keep Seven & i away from Canada’s Alimentation Couche-Tard, which announced a takeover proposal in August. The Circle K owner raised its bid for Seven & i by about 22 per cent to US$47 billion in October after its initial offer was rejected. The scramble for Seven & i gives a taste of how deals are likely to develop in the years to come, industry experts say, as changes in Japan Inc’s corporate governance standards make delisting an increasingly compelling option. A few years ago, companies could ignore unsolicited offers because they were protected by cross shareholdings - the practice of holding stakes in business partners to cement relationships. But those holdings are now being sold off under a government push for better governance. Companies have also been told they should give serious consideration to credible buyout offers. “Managers can no longer ignore shareholders as they could in the past. Cross shareholdings are being unwound all the time,” said Travis Lundy of Quiddity Advisors who publishes on the Smartkarma platform. “MBOs are going to be more common,” Lundy said, adding the government’s guidelines on giving consideration to buyout offers were “a game changer”. All in the family Last year, Japanese deals where management took stakes, including MBOs, totalled US$7.1 billion, the most in at least 36 years, LSEG data showed. The value has fallen from that peak this year, but remains at US$1.7 billion. Among recent deals, educational publisher and nursing home operator Benesse Holdings was taken private in an MBO by the founding Fukutake family and Swedish private equity firm EQT. Drugmaker Taisho Pharmaceutical was bought out by a member of its founding Uehara family. MBOs are becoming an attractive option because the governance overhaul has created bigger burdens for listed firms, while being a public company no longer confers the status it once did, said Ulrike Schaede, a professor of Japanese business at the University of California San Diego. Schaede gives the example of Germany, where MBOs have become a “new defence” against shareholder activism, adding that Japan could start to see a similar trend, especially given private equity’s appetite for deals in the country. Japan is hardly the only place where founding families hold stakes and sway after the founder dies - and Seven & i not the only global retailer in that position. The family of Walmart founder Sam Walton holds 45.5 per cent of the US retailer, while the largest shareholders of Sweden’s H&M are Stefan Persson, son of the founder, and his family. Small stakes But Japan stands out because families are able to wield considerable power despite holding small stakes. Ito-Kogyo, the company tied to Junro Ito that is bidding for Seven & i, holds only about 8.2 per cent of the retailer. Historically, family control of businesses in Japan has been “more persistent than the very low equity ownership by founding families would indicate”, researchers from the University of Copenhagen, the University of Alberta School of Business and elsewhere wrote in a 2021 Journal of Financial Economics paper. Some 10 per cent to 30 per cent of listed Japanese companies from the 1960s to 2010 were managed by founding family heirs with “little ownership to report”, Morten Bennedsen, Vikas Mehrotra and their co-authors found. They pointed to examples such as the Toyoda family at Toyota Motor, the Suzukis of Suzuki Motor and the Kashios at Casio Computer. Such families were able to retain control via what the researchers called “soft family assets”, including their name and reputation. “We certainly expect that the trend is continuing, there is no sign it is changing,” Bennedsen told Reuters. One Seven & i investor recalled attending a meeting with company executives including Junro Ito, who sat silent throughout. The extent to which the Ito family wielded influence and power within the company was “something of a mystery”, said the investor, who asked not to be named due to company policy. A Seven & i spokesperson declined to comment. At many companies, the founder’s legacy still looms large. In recent years Seven & i resisted calls from foreign investors to hive off its Ito-Yokado supermarkets’ business out of respect for founder Masatoshi Ito’s vision, according to veteran Japan retail analyst Michael Causton. “The Ito legacy, as in many Japanese companies with a charismatic founder, is an unwritten red line in the company known to all executives,” Causton said, adding that amounted to preserving Seven & i as a conglomerate spanning supermarkets, general merchandise and convenience stores. It remains to be seen whether the Ito family will manage to raise the funds needed for the deal - although it appears that domestic banks are lining up with them. What is clear is that more such deals are likely to happen, something investors welcome. “If the founding families in Japan really want to control and influence their companies, then they shouldn’t be listed and instead taken private,” the Seven & i investor said. REUTERS
Trump offers support for dockworkers union by saying ports shouldn't install more automated systemsPep vows Man City turnaround: 'I won't give up'Bill Belichick spent 48 years coaching in the NFL, nearly half of which was spent turning the New England Patriots into one of the greatest dynasties the sport has ever seen. Now, the NFL's second-winningest coach (including playoffs) is reportedly taking on a new challenge: college football . Belichick has agreed to become the new head coach at North Carolina , according to multiple reports. The agreement will land the 72-year-old his first college head coaching job on what The Athletic reports will be a three-year, $30 million contract. Belichick will need to quickly acclimate to working with younger players and get used to the massive yearly roster turnover that has come with the transfer portal. Those will be just two of the factors that will make Belichick's transition to college coaching fascinating to watch. But the main one? No NFL coach with Belichick's level of success has ever dropped from the professional to the college ranks. It will be on him to prove that his unparalleled NFL achievements can also be had at the NCAA level. NFL STATS CENTRAL: The latest NFL scores, schedules, odds, stats and more. Here's more on just how unprecedented Belichick's transition to college football will be. The latest: Bill Belichick finalizing deal to become North Carolina football coach, per reports College coaches with the most NFL wins Belichick will be the winningest NFL coach to coach at the college level. He has racked up a whopping 302 regular-season wins during his NFL coaching career (333 wins if you count the playoffs); no other coach to go from the NFL to college has ever had more than 95 (Lou Saban). Below is a look at the coaches who had 40-plus NFL regular-season wins when they took on college coaching jobs, according to data from Pro Football Reference : Some of the coaches listed above ended up jumping back from the college ranks to the NFL, which might be what Belichick is hoping to accomplish. As such, some ended up with higher win totals than those listed above, but only after their college coaching careers were complete. That's why Pete Carroll didn't make it onto the list above. He had 33 NFL wins before he began coaching at USC in 2001. Upon his split with the Seattle Seahawks following the 2023 NFL season, he had 170 NFL wins to his name. BILL BELICHICK TO UNC: Coach makes pitch to recruits for job on 'Pat McAfee Show' Most wins in college football history Below is a look at the winningest coaches in college football history, headlined by Penn State's Joe Paterno. NFL ON CHRISTMAS: Netflix announces star-studded broadcaster lineup for holiday games Most wins in NFL history Belichick ranks third all-time in NFL regular-season wins. Below are the 10 winningest coaches from the league's history. All the NFL news on and off the field. Sign up for USA TODAY's 4th and Monday newsletter .
Friendly reminder |
The authenticity of this information has not been verified by this website and is for your reference only. Please do not reprint without permission. If authorized by this website, it should be used within the scope of authorization and marked with "Source: this website". |
Special attention |
Some articles on this website are reprinted from other media. The purpose of reprinting is to convey more industry information, which does not mean that this website agrees with their views and is responsible for their authenticity. Those who make comments on this website forum are responsible for their own content. This website has the right to reprint or quote on the website. The comments on the forum do not represent the views of this website. If you need to use the information provided by this website, please contact the original author. The copyright belongs to the original author. If you need to contact this website regarding copyright, please do so within 15 days. |